Country: Canada
Language: English
Source: Health Canada
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
APOTEX INC
J05AR06
EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
600MG; 200MG; 300MG
TABLET
EFAVIRENZ 600MG; EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG
ORAL
30/90
Prescription
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0352327001; AHFS:
APPROVED
2017-09-14
Page 1 of 77 PRODUCT MONOGRAPH PR APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS APOTEX STANDARD 600 MG EFAVIRENZ 200 MG EMTRICITABINE 300 MG TENOFOVIR DISOPROXIL FUMARATE ANTIRETROVIRAL AGENT APOTEX INC. Date of Revision: 150 Signet Drive June 24, 2020. Toronto, Ontario M9L 1T9 Submission Control No.: 239967 Page 2 of 77 TABLE OF CONTENTS PART I. HEALTH PROFESSIONAL INFORMATION ........................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 16 DRUG INTERACTIONS ......................................................................................................... 25 DOSAGE AND ADMINISTRATION ..................................................................................... 42 OVERDOSAGE ....................................................................................................................... 43 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 44 STORAGE AND STABILITY ................................................................................................. 48 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 48 DOSAGE FORMS, COMPOSITION AND PACKAGING..................................................... 48 PART II. SCIENTIFIC INFORMATION ................................................................................... 49 PHARMACEUTICAL INFORMATION .......... Read the complete document